DURHAM — Fortrea, a prominent contract research organization listed on Nasdaq (FTRE), has today announced a strategic partnership with Medidata, a subsidiary of Dassault Systèmes and a leader in clinical trial solutions. This collaboration aims to leverage Medidata’s AI Intelligent Trials technology to broaden the diversity of participants in Fortrea-conducted clinical trials.

This partnership builds upon Fortrea’s existing use of Medidata’s Rave EDC solution, a system for capturing and managing clinical trial sites, patients, and laboratories, as well as capturing data. The integration of Medidata’s AI Intelligent Trials allows Fortrea to enhance its services for biopharmaceutical companies, as well as for medical device and diagnostic firms. The technology focuses on the feasibility of studies, and providing diversity data to aid companies in meeting enrollment targets that truly represent the populations affected by various diseases or conditions.

Labcorp spinoff Fortrea stock climbs; activist investor wants changes

Diversity in clinical trials has long been an issue due to a lack of communication and trust with minority communities. Mark Morais, Fortrea’s COO and President of Clinical Services, and Fareed Melhem, SVP at Medidata AI both commented on the importance of including diverse populations in the press release.

“Together, our solutions support customers in life sciences to accelerate study timelines and make the benefits of clinical therapies more accessible to a diverse spectrum of individuals,” said Melhem.